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Abstract
Burkholderia pseudomallei is a Gram-negative bacterium responsible for melioidosis, a seri-
ous and often fatal infectious disease that is poorly controlled by existing treatments. Due to
its inherent resistance to the major antibiotic classes and its facultative intracellular patho-
genicity, an effective vaccine would be extremely desirable, along with appropriate preven-
tion and therapeutic management. One of the main subunit vaccine candidates is flagellin
of Burkholderia pseudomallei (FliCBp). Here, we present the high resolution crystal structure
of FliCBp and report the synthesis and characterization of three peptides predicted to be
both B and T cell FliCBp epitopes, by both structure-based in silicomethods, and sequence-
based epitope prediction tools. All three epitopes were shown to be immunoreactive against
human IgG antibodies and to elicit cytokine production from human peripheral blood mono-
nuclear cells. Furthermore, two of the peptides (F51-69 and F270-288) were found to be
dominant immunoreactive epitopes, and their antibodies enhanced the bactericidal activi-
ties of purified human neutrophils. The epitopes derived from this study may represent
potential melioidosis vaccine components.
Author Summary
Melioidosis is an infectious disease caused by Burkolderia pseudomallei that poses a major
public health problem in Southeast Asia and northern Australia. This bacterium is difficult
to treat due to its intrinsic resistance to antibiotics, poor diagnosis, and the lack of a
licensed vaccine. Vaccine safety is a prime concern, therefore recombinant protein subunit
and/or peptide vaccine components, may represent safer alternatives. In this context, we
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Based on the knowledge that activation of both cell-mediated and antibody-mediated
responses must be addressed in a melioidosis vaccine, we identified B and T cell immuno-
reactive peptides from FliCBp, using both sequence-based and structure-based computa-
tional prediction programs, for further in vitro immunological testing. Our data confirm
the accuracy of sequence-based epitope prediction tools, and two structure-based methods
applied to the FliCBp crystal structure (here-described), in predicting both T- and B-cell
epitopes. Moreover, we identified two epitope peptides with significant joint T-cell and B-
cell activities for further development as melioidosis vaccine components.
Introduction
Burkholderia pseudomallei, a pathogenic Gram-negative bacterium present in soil and water, is
responsible for melioidosis, an often fatal infectious disease that is most frequently reported in
tropical regions of the world, especially in Thailand and northern Australia, where the disease
is endemic [1]. Diagnosis and treatment of melioidosis are far from adequate, as symptoms
lack a specific signature necessary for rapid diagnosis, and the bacterium is inherently resistant
to many commercially available classes of antibiotics. In addition, due to the intrinsically poly-
morphic nature of the pathogen, infections can occur in acute and chronic forms, with a pleth-
ora of different clinical manifestations [2]. Over the last few years, the study of melioidosis has
become increasingly relevant, not only as a public health concern, but also due to bioterrorism
implications, since B. pseudomallei is classified as a category B infective agent.
To date, no melioidosis vaccine is available, and no vaccine candidates are close to licensing
[3,4]. Furthermore, the use of attenuated forms of B. pseudomallei presents significant safety
issues due to its capacity to remain dormant and cause infections years later, therefore it is
clear that alternative approaches must be sought.
A subunit vaccine approach, whereby only the microbial components that produce an
appropriate immune response are administered, offers a means to significantly improve vac-
cine safety [5]. One safer alternative is a peptide-based vaccine approach, since peptides are
easily and inexpensively produced [6]. Although subunit vaccines present many desirable qual-
ities, their ability to stimulate a potent immune responses is much weaker than traditional
whole-cell preparations. This may explain why no effective vaccine candidates against B. pseu-
domallei infection have emerged, despite several attempts using different approaches [7].
According to previous studies, protection against B. pseudomallei infection requires optimal
responses from both cellular and humoral immune systems [7,8]. IFN-γ secreted by NK cells
and T cells plays an important role in the control of infection in mice [9]. To date, one of the
main candidate antigens is bacterial flagellin (FliC), which assembles to form the flagellar fila-
ment that supports bacterial motility. FliC induces IFN-γ responses from human T cells, and is
recognized by antibodies from seropositive individuals living in endemic areas [10,11]. In a
mouse model of infection, CpG-modified plasmid DNA encoding flagellin, induced responses
from Th1 cells and B cells, and was shown to protect against bacterial re-infection and to
reduce mortality and morbidity rate [11]. Furthermore, in passive immunization trials, anti-
bodies raised against FliC from B. pseudomallei strain 319a were shown to protect diabetic rats
challenged with a heterologous B. pseudomallei strain [12,13].
Interestingly, FliC is recognized as a pathogen associated molecular pattern (PAMP) by
Toll-like receptor 5 (TLR5) and by nucleotide-binding oligomerization domain (NOD)-like
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receptor C4 (NLRC4), activating both innate and adaptive immunity [14,15]. Indeed, both are
pattern recognition receptors (PRR), and play a key role in innate immunity, offering a first
line of defence against invading pathogens. PAMPs are prevalent in bacterial but not in verte-
brate genomic DNA; the immune system appears to exploit these molecules as signaling bea-
cons to reveal the presence of infection and activate appropriate defense pathways [16]. It has
been proven that TLR5 interacts with the conserved D1 domain of FliC, responsible for flagel-
lin assembly [17]. Therefore, in addition to the direct stimulation of a protective response, FliC
could function as a molecular adjuvant in combination with other specific antigen(s) [18].
With regards to flagellin from B. pseudomallei (FliCBp), epitope mapping, performed in our
laboratory at Khon Kaen University, Thailand by synthesis of 38 multiple overlapping peptides
extending along the whole protein sequence was carried out and identified several peptides
that bound to HLA class II alleles found in Thailand [19]. This approach, however, is costly
and time consuming. Sequence-based and 3D structure-based computational predictions for
consensus dominant epitopes represent alternative, inexpensive and rapid approaches for epi-
tope discovery and vaccine development [20].
In this report, we focused on FliCBp as a target antigen for sequence and structure-based epi-
tope discovery. On this basis, we designed and synthesized the predicted epitopes as free pep-
tides for consideration as potential vaccine components. To this aim, we used three B-cell
epitope prediction servers [21,22] and one T-cell epitope prediction server [23], to identify
putative ab initio immunoreactive linear epitopes. Analysis of the sequence outputs from all
servers resulted in the identification of three linear epitopes with predicted B-cell and T-cell
activities. The three selected sequences were synthesized as conjugated peptides, and tested for
their effective T-cell/B-cell activities in immunological studies.
In parallel, we solved the high-resolution crystal structure of FliCBp as a starting point for
future structure-based antigen and epitope design and optimization that permitted the identifi-
cation of additional potentially antigenic regions. To this aim, we used a combination of 3D
structure-based epitope predictions [24,25] and an experimental epitope mapping technique to
broaden our consensus toward the identification of novel epitopes. Upon comparison of
sequence-based and structural T-cell predictions, we identified and synthesized an additional
T-cell epitope that was also tested in immunological studies.
FliCBp constitutes a major target for vaccine discovery initiatives to elicit protective immu-
nity against B. pseudomallei infections. The predicted epitope sequences here-identified, cou-
pled to the structural information about their native conformations, hold great potential for a
process of rational design toward the optimization of their antigenic properties, and display the
characteristics required for presentation as vaccine components.
Materials and Methods
Blood samples
Ethical permission was obtained from the KKU Ethics Committee for Human Research no.
HE470506 and HE561234. All subjects were adults and had received written information
before signing the consent form. Heparinized whole blood samples were collected from healthy
donors, seropositive (IHA titer> 40) and seronegative (IHA titer 40) individuals [26,27], at
the Blood Bank Center, Khon Kaen University, and from recovered melioidosis patients at Sri-
nakarind Hospital, Khon Kaen University, Khon Kaen, Thailand.
Prediction of B and T cell epitopes using web servers
The full-length FliCBp protein sequence was submitted to B cell linear epitope predictors,
BepiPred (http://www.cbs.dtu.dk/services/BepiPred/) [21]; threshold = 0.35, BCPred (http://
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ailab.ist.psu.edu/bcpred/predict.html) [22]; classifier specificity = 75%, and AAP (http://ailab.
ist.psu.edu/bcpred/predict.html) [22]; classifier specificity = 75%). Any sequences that were
positively selected by more than two prediction methods and that contained more than 15
amino acids were selected as linear B cell epitopes. Predicted linear B cell epitopes were then
re-submitted for T cell epitope predictions using the MHC-II Binding Predictor (http://tools.
immuneepitope.org/mhcii/) in the Immune Epitope Database (IEDB) [23], with HLA DRB1
alleles common to Thailand; HLA DRB10301, 0405, 07, 09, 1202, 1501, 1502 and 1602 [28].
Positive T cell epitopes were identified by a HLA binding prediction score of less than 30.
Recombinant FliCBp production, crystallization, data collection, and
structure determination
The BPSL3319; fliC gene encoding for protein residues 25–378 (devoid of the N-terminal signal
peptide (1–24) and C-terminal residues 379–388), was amplified from B. pseudomallei strain
K96423 (Kindly provided by Prof. R. Titball, University of Exeter, UK), cloned into pGEX4T1
(Life Technologies) and expressed as a GST-fusion protein in BL21 Star (DE3) Escherichia coli
cells (Life Technologies) and purified by affinity chromatography on a 5mL GSTrap FF column
(GE Healthcare) pre-equilibrated in 1X PBS. On-column cleavage of the GST tag was carried
out upon addition of 100 U thrombin (Sigma-Aldrich) in 1X PBS, incubation overnight at RT.
Cleaved FliCBp was eluted with 1X PBS and thrombin was removed using a 1ml HiTrap Benza-
midine FF column (GE Healthcare), according to the manufacturer’s instructions. FliCBp was
exchanged into 10 mM Tris-HCl pH 8.0 and concentrated to 10.5 mg/ml for crystallization
trials.
FliCBp crystals were grown by sitting drop at 20°C, in a 300 nl drop containing 50% protein
solution (10.5 mg/ml) and reservoir solution (0.1 M HEPES pH 7.5, 25% PEG 6000 and 0.1 M
Lithium Chloride). Crystals were cryo-protected in reservoir solution containing 30% glycerol.
One crystal was used to collect X-ray diffraction data at the ID23-2 beamline at the European
Synchrotron Radiation Facility (Grenoble, France). Data were processed using IMOSFLM and
scaled using POINTLESS and SCALA using the CCP4 suite [29,30]. The structure was solved
via molecular replacement using Phaser [31] and the structure of domain D1 (residues 62–168
and 281–326) of Sphingomonas sp. A1 flagellin (PDB entry 2ZBI) as a search model (the struc-
ture of FliCPa was not available at that time). Residues of the search model not conserved in
FliCBp were substituted with alanines. The experimental phases were improved by applying
Arp/Warp [32], and the amino acid sequence of the model was then modified to match the cor-
rect FliCBp sequence. The FliCBp structure was completed by manually fitting in the electron
density residues of the D2 domain, which inserts between residues 167 and 287 of domain D1.
Several rounds of manual model building with COOT [33], and refinement with the program
REFMAC5 [34], were carried out until refinement reached convergence and the quality of the
model was checked with PROCHECK [35]. The final refinement statistics and geometry qual-
ity parameters are shown in S1 Table. Atomic coordinates and structure factors were deposited
in the Protein Data Bank with PDB code 4CFI [36].
Epitope prediction and design
The crystal structure of FliCBp was used as a starting point for three replicas of all-atom Molec-
ular Dynamics (MD) simulations in explicit water at 300K. Each replica was 50 ns long and
was carried out in NPT conditions. The simulations and the analysis of the trajectories were
performed using the GROMACS 4.54 software package [37],[38], the SPC water model [39]
and the GROMOS53A6 force field [40]. The procedure employed is fully described in Gourlay
et al., [41].
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Matrix of Local Coupling Energies (MLCE) method
Epitope predictions were carried out using MLCE on the representative structure of the most
populated structural cluster of each MD trajectory [24]. The clustering procedure was performed
using the method developed by Daura et al [40]. The MLCE method is based on the calculation
of the matrix of inter-residue, non-bonded interaction energies using a MM-GBSA (Molecular
Mechanics Generalized Born Surface Area) implicit solvent approximation. The principal com-
ponents of the interaction matrix are selected by eigenvalue decomposition [42,43,44,45,46] and
filtered by the protein contact map to select the substructures presenting low energy couplings
with the rest of the protein 3D fold. These substructures are characterized by dynamic properties
allowing them to visit multiple conformations, a subset of which can be recognized by the anti-
body. MLCE is available as the free web tool BEPPE (http://bioinf.uab.es/BEPPE).
Electrostatic Desolvation Profiles (EDP) method
The EDP method calculates the free energy penalty for desolvation placing a neutral probe at
various protein surface positions. Surface regions with a small free energy penalty for water
removal may correspond to preferred interaction sites. Evidence suggests that it is easier for an
antibody to bind to an epitope when properties required for high affinity binding like low deso-
lvation penalty are met [25].
In vitro epitope mapping
Peptide mixtures were obtained by trypsin digestion of recombinant FliCBp in 50 mM ammo-
nium bicarbonate buffer (pH 7.8) at a ratio of 10:1, at 37°C for 3 h. To capture the epitope-con-
taining peptide, a 25 μl suspension of Dynabeads Pan Mouse IgG (uniform, super-
paramagnetic polystyrene beads of 4.5 μm diameter coated with monoclonal human anti-
mouse IgG antibodies) was used. The beads were washed twice with PBS using a magnet and
re-suspended in the initial volume. 50 μl of the murine serum were added and incubated for 30
min at room temperature (RT), after which the beads were washed five times with PBS to
remove serum debris. 0.5 μl of Protease Inhibitor Mix (GE healthcare) were added before the
peptide mixture to avoid potential antibody degradation. The sample was then incubated for 2
h at RT with gentle tilting and rotation. After incubation, beads were washed three times with 1
ml PBS, and the bound peptides were eluted in 50 μl of 0.2% TFA. The elution fraction was
concentrated and washed with C18 ZipTips (Millipore) and eluted in 2 μl of 50% ACN and
0.1% TFA. Subsequent MALDI-MS analysis of the eluted fractions was carried out. For more
details, see Gourlay et al., [41].
Peptide synthesis
All peptides were manually assembled by stepwise Fmoc-SPPS onto a 2-Chlorotrityl chloride
resin (2-CTC), using HBTU/DIEA for in situ activation of entering amino acids [47]. Piperi-
dine 20% in DMF was used for Fmoc removal steps. Cysteine was added to the N- of peptides
to enable specific conjugation to carrier proteins, using poorly immunogenic PEG units as
spacers. Upon completion of peptide assembly, peptides were simultaneously cleaved from the
resin and side chains were deprotected by treatment with a mixture of 2.5% water, 2.5% thioa-
nisole, 2.5% ethanedithiol, 2.5% triisopropylsilane and 90% trifluoroacetic acid for 2 hours at
RT. Crude peptides were precipitated in cold diethyl ether, collected by centrifugation and
washed with further cold ether Peptides were subsequently dissolved in 50% aqueous ACN/
0.1% TFA and purified by C18-RP-HPLC. Peptide purity and identity was assessed by analyti-
cal C18-RP-HPLC and separate ESI-MS analysis.
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Peptide conjugation to carrier proteins and polyclonal anti-peptide
preparation
Peptide N-terminal cysteine residue, preceded by the PEG spacer, allowed selective conjugation
to carrier proteins (human serum albumin, (HSA), Hemocyanin from Concholepas (KLH) and
Rabbit Serum Albumin (RSA)) using sulfosuccinimidyl 4-(N-maleimidomethyl) cyclohexane-
1-carboxylate (Sulfo-SMCC) bifunctional linker. All peptides were prepared in free- and conju-
gated forms. Polyclonal antibodies were raised against peptide epitopes in rabbits (Primm srl,
Milano Italy). Antisera against the FliCBp peptides were immunopurified against the peptides
chemically linked to Cyanogen Bromide Activated Sepharose (Sigma-Aldrich).
Detection of rabbit or human antibodies (IgG) in serum by indirect ELISA
Rabbit or human antibody recognition was detected as previously described [41]. In brief,
96-well polystyrene plates (Nunc Maxisorp) were uncoated or coated with 50 μl/well of 1 μg/
ml of B. pseudomallei K96243 crude extract (crude Bps), 3 μg/ml of FliCBp protein or HSA-con-
jugated predicted peptides or HSA in 0.1 M carbonate-bicarbonate buffer (pH 9.6), and incu-
bated at 37°C for 3 hr. After washing, 50 μl/well of 1:300 diluted human plasma or 1:3,000
rabbit antisera samples were probed in duplicate. Immunoreactivity was detected and repre-
sented as absorbance index of individual samples = (O.D.test−O.D.uncoated) / O.D.uncoated.
In vitro human peripheral blood mononuclear cell (PBMC) stimulation
and cytokine detection by indirect ELISA
PBMCs from each donor were isolated by density gradient centrifugation on Ficoll-Hypaque
and stored at -80°C with 10% dimethyl sulfoxide (DMSO) in fetal bovine serum (FBS). Imme-
diately prior to the experiment, frozen PBMCs were thawed and resuspended in RPMI 1640,
supplemented with 10% FBS, 200 U/ml penicillin, and 200 mg/ml streptomycin. 5 x 105
PBMCs/well were plated in 96-well culture plates and cultured with fixed Bps (PBMCs:organ-
ism = 1:30), 3 μg/ml of phytohaemagglutinin (PHA), 10 μg/ml of recombinant FliCBp, and 50
g/ml peptides for 48 h. Gamma interferon (IFN-γ) and interleukin 10 (IL-10) levels in the
supernatant were quantified using a cytokine detection ELISA kit (BD biosciences) according
to the manufacturer’s instructions. The sample with a detectable cytokine level higher than the
lower limit of detection (>45 pg/ml) was described as responder.
Polymorphonuclear (PMN) cell phagocytosis and oxidative burst assay
Human PMN cells were purified by 3.0% dextran T-500 sedimentation and Ficoll-PaquePLUS
centrifugation (Amersham Biosciences), as previously described [41]. Generally, PMN cell
purity was>95%, as determined by Giemsa staining and microscopy; viable cells were counted
by trypan blue exclusion (viability>99%). 1 x 109 CFU/ml of intact B. pseudomallei K96243
cells were labeled with 1 mg/ml of FITC in the dark at room temperature for 1 h. Intensity FITC
on labeled bacteria was measured by flow cytometry. 7.5 x 107 CFU/ml FITC-labeled bacteria
were treated with medium alone or antibody at concentrations of 40 μg/ml, for 1 h at 37°C,
before being cultured with purified human PMN cells for 15 min at 37°C. 1:50 rabbit anti-FliCBp
antisera was used as positive control for phagocytosis assay, while, 800 ng/ml of PMA (Sigma-
Aldrich) was used as a positive control for the oxidative burst assay. Subsequently, 25 μl of 2,800
ng/ml of hydroethidine (HE) (Sigma-Aldrich) was added and incubated for 5 min at 37°C,
washed twice and fixed with 2% paraformadehyde. Phagocytosis of FITC labeled Bps+ and oxi-
dative burst activities of PMN cells that turn hydroethidine (HE) to ethidium bromine (EB+)
were analyzed by flow cytometry (FACSCalibur; BD Biosciences). Results are represented as %
Sequence- and Structure-Based Immunoreactive Epitopes of Flagellin
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003917 July 29, 2015 6 / 20
phagocytosis (total % FITC+) and % oxidative burst (% EB+ FITC+) (details shown in S1 Fig).
The differences between antibody groups were tested by the paired t test.
Intracellular bacterial killing assay
Live B. pseudomallei K96243 was opsonized, with or without 1 μg/ml of anti-FliCBp peptide
antibodies, as described above. Rabbit pre-breed serum at 1:50 was used as negative control
while rabbit anti-FliCBp antiserum at 1:50 was used as positive control.
Purified human PMN cells at 5 x 105 cells were incubated with opsonized bacteria (multiply
of infection; MOI = 10) for 30 min at 37°C. Extracellular bacteria were subsequently killed
upon addition of 250 μg/ml of kanamycin for 30 min, at this time point; PMN cells were lysed
and plated on LB agar for bacterial counts (T0). In another condition, 20 μg/ml of kanamycin
was added to maintain extracellular bacteria and incubated for 3 h at 37°C, and bacteria num-
bers were counted (T3).
Results
Sequence-based prediction of FliCBp B- and T-cell linear epitopes
Epitope predictions were carried out on the full-length (residues 1 to 388) amino acid sequence
of FliCBp (UNIPROT code H7C7G3), using the web-accessible prediction servers BepiPred,
BCPred and AAP [21,22]. Six linear B cell epitopes were identified (Fig 1) and subsequently
used for T cell epitope predictions using the IEDB server [23,48] (www.iedb.org), selecting for
HLA DRB1 alleles common in Thailand; HLA DRB10301, 0405, 07, 09, 1202, 1501, 1502 and
1602 [28]. A detailed overview of the consensus between linear epitopes predicted by
sequence-based web servers is shown in Fig 1. The top three epitopes that were predicted to be
both B and T cell epitopes are F51-69, F96-111 and F270-288. Interestingly, F51-69 overlaps
with Peptide 6 (residues 51–70); F96-111 overlaps with Peptide 10 (residues 91–110), and
F270-288 overlaps with Peptide 28 (residues 271–290) from the peptide panel synthesized by
Musson et al. The following peptides were synthesized as described in the Materials and Meth-
ods section: F51-69; 51-TRMQTQINGLNQGVSNAND-69, F96-111; 96-VQASNGPLSASDA-
SAL-111, F270-288; 270-NATAMVAQINAVNKPQTVS-288.
Predicted FliCBp epitope peptides, F51-69 and F270-288 are recognized
by human antibodies (IgG) in serum, and also elicit responses from
human PBMCs
Predicted B and T cell epitopes were initially evaluated for immunorecognition by probing
them with rabbit anti-FliCBp anti-sera. All three peptides were recognized (Fig 2). Subse-
quently, crude B. pseudomallei extract (Bps), recombinant FliCBp, and peptides F51-69, F96-
111 and F270-288 were tested against human plasma samples for immunorecognition (Fig 3).
In order to investigate a possible role of the peptides in protection, samples were tested from
diverse sub-populations, including healthy seronegative, healthy seropositive and recovered
melioidosis patient groups. Results showed that F51-69 and F270-288 were recognized by anti-
bodies in human plasma, in contrast to F96-111. In addition, antisera from recovered individu-
als were shown to recognize Bps extract, FliCBp, and all peptides, except for F96-111, to a
greater extent than those from healthy seropositive and seronegative individuals (Fig 3).
Moreover, upon comparison of antibody reactivity between healthy sample groups, we
found that the levels of reactivity to crude Bps, F51-69 and F270-288 in the seropositive group
were significantly higher than those in the seronegative group, p< 0.001, p< 0.001 and
p< 0.05, respectively (Fig 3B). In case of FliCBp, there was a background of antibodies in
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seronegative group that might be due to B. thailandensis flagellin as it shares 91% similarity to
B. pseudomallei flagellin compared by Basic Local Alignment Search Tool (BLAST). However,
the levels of antibody against FliCBp in melioidosis recovered group were significantly higher
than both seronegative and seropositive groups. Taken together, this suggests that people who
are exposed and/or infected with B. pseudomallei develop antibodies against FliCBp, and more
specifically against F51-69 and F270-288 epitopes (Fig 3). In contrast, peptide F96-111 was not
recognized in human samples, despite high reactivity against rabbit anti-sera. This is likely due
to the fact that this peptide is accessible in the recombinant protein, but not when FliCBp is
assembled in the flagella, as supported by the observation that antibodies raised against F96-
111 do not recognize crude B. pseudomallei (S2B Fig).
An additional confirmation of antibody specificity was illustrated by coating ELISA plates with
crude Bps extract and each synthesized peptide. Each plate was probed with human plasma sam-
ples, previously neutralized with the same extract/peptide at different concentrations (S3 Fig).
According to this test, peptides F51-69 and F270-288 inhibited the activity of antibodies in the rec-
ognition of their corresponding sample coated on the plate in a dose-dependent manner (S3 Fig).
Fig 1. FliCBp B-cell linear sequence-based epitope predictions using three predictor methods: BepiPred (threshold = 0.35), BCPred (classifier
specificity = 75%), and AAP (classifier specificity = 75%). Epitope predictions were carried out on the full-length amino acid sequence of FliCBp, using
three web-accessible prediction servers: BepiPred, BCPred and AAP [21,22]. Predicted epitope residues by BepiPred, BCPred and AAP are shown in red,
blue and green font, respectively on the amino acid sequence (residue numbers are indicated). Grey shaded boxes indicate consensus positive residues
identified by at least two epitope predictors.
doi:10.1371/journal.pntd.0003917.g001
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Following our analysis of the FliCBp crystal structure (see below) and comparison with FliC
from S. typhimurium, it became apparent that F96-111 is located in a region of the protein that
mediates monomer-monomer interactions during assembly of FliC into its 11-subunit ring
protofilament arrangement [49]. Therefore, when FliCBp is assembled in its native form in the
flagella, this region would not be solvent accessible, in agreement with its lack of recognition by
human antibody.
To further our studies, we then assessed whether the peptides could be active as human T
cell epitopes, as implied by the bioinformatics predictions. Peptides were cultured with healthy
PBMCs for 48 h, and the culture supernatants were measured for IFN-γ and IL-10 production
using ELISA, as described in the Materials and Methods. We found that almost all samples
(19/20; 95%) responded to intact killed Bps via IFN-γ production, some responded to FliCBp
(13/20; 65%), F51-69 (15/20; 75%), F96-111 (9/20; 45%) and F270-288 (7/20; 35%), as shown
in Fig 4. According to our results, FliCBp protein and predicted epitope peptides, in particular
F51-69, elicited IFN-γ production from human PBMCs. With regards to an IL-10 response, all
samples responded to fixed Bps, although with variable intensity. Recombinant FliCBp and
peptide F51-69 responded in all samples (100%), however only 13/20 samples responded to
F96-111 (65%) and 16/20 samples to F270-288 (80%). By combining the results of immunore-
activity against patient sera and the stimulation of cytokine production, we may confirm that
epitopes F270-288 and F51-69, in particular, are promising B cell and T cell epitopes.
Antibodies against FliCBp, F51-69 and F270-288 enhance phagocytosis,
oxidative burst and bacterial killing in primary human neutrophils
Our results show that antibodies against F51-69 and F270-288 are present in plasma of healthy
donors who have been exposed to B. pseudomallei. Therefore we aimed to investigate whether
these antibodies may stimulate phagocytosis by neutrophils and induce bacterial killing. Rabbit
Fig 2. Recognition of predicted epitope peptides by rabbit anti-FliCBp sera as detected by Indirect
ELISA.Controls (A) composed of human serum albumin (HSA), crude B. pseudomallei, recombinant FliCBp,
without primary antibody (No 10 Ab) and without secondary antibody (No 20 Ab) and F51-69, F96-111, F270-
288 and F213-231 peptides (B) were coated at various concentration (1, 3 and 10 μg/ml) onto a 96-well
polystyrene plate and probed with diluted rabbit antibodies to FliCBp and quantified by indirect ELISA. Results
are represented by the Absorbance index (O.D.test−O.D.uncoated / O.D.uncoated). Experiments were performed
in duplicate and results represent the mean of the Absorbance index ± SE.
doi:10.1371/journal.pntd.0003917.g002
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polyclonal antibodies were raised against F51-69 and F270-288 peptides (see Materials and
Methods). Prior to experiments, the activity of antibodies against intact B. pseudomallei,
recombinant FliCBp and peptides were checked by indirect ELISA. Results showed that all rab-
bit antisera recognized intact B. pseudomallei, recombinant FliCBp and immunized peptides
(S3 Fig). Antibodies were subsequently used in B. pseudomallei opsonization tests and analyzed
for bacterial phagocytosis and oxidative burst production in human neutrophils. Results
revealed that antibodies raised against recombinant FliCBp and predicted epitope peptides
enhance both phagocytosis and oxidative burst activity in human neutrophils (Fig 5A and 5B).
Interestingly, we also found that these antibodies also enhance bacterial uptake and intracellu-
lar bacterial killing in human neutrophil infection studies (Fig 5C). These results suggest that
antibodies against F51-69 and F270-288 may enhance host resistance to B. pseudomallei infec-
tion by stimulating neutrophil phagocytosis and bacterial killing.
3D structural analyses of FliCBp by X-ray crystallography
FliCBp (residues 25 to 378) was crystallized using the sitting drop vapor diffusion method, as
described in the Materials and Methods section. The crystal structure of FliCBp was solved at a
Fig 3. Distribution of human antibody againstB. pseudomallei related proteins and peptides among
seronegative (S-; n = 24), seropositive (S+; n = 24) andmelioidosis recovered individuals (R; n = 24),
detected by Indirect ELISA.Crude B. pseudomallei antigens (A) recombinant FliCBp (B), FliCBp peptide
F213-231 (C), F51-69 (D), F96-111 (E), F270-288 (F) were coated onto a 96-well polystyrene plate and
probed with diluted plasma samples from healthy and recovered individuals and quantified by indirect ELISA.
Results are represented by the Absorbance index (O.D.test−O.D.uncoated / O.D.uncoated). Experiments were
performed in duplicate and results represent the mean of the Absorbance index ± SE. * P < 0.05, ** P < 0.01,
*** P < 0.001, ns = not significant compared between plasma sample groups using one-tailed Mann-Whitney
U test.
doi:10.1371/journal.pntd.0003917.g003
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Fig 4. FliCBp peptides induce human IFN- and IL-10 production from PBMCs. PBMCs (5 x 10
5 cells/well) from 20 seropositive healthy donors were
stimulated with culture medium alone (Med), fixed Bps (PBMCs:organism = 1:30), 3 μg/ml of phytohaemagglutinin (PHA), 10 μg/ml of FliCBp protein, and 50
g/ml of FliCBp peptides (F51-69, F96-111, F270-288 and F213-231) for 48 h, and the IFN- and IL-10 levels were quantified by ELISA. Vertical lines represent
the median and dashes indicate the detection limit.
doi:10.1371/journal.pntd.0003917.g004
Fig 5. Rabbit anti-FliCBp predicted peptide antibodies enhance phagocytosis (A), oxidative burst (B) and bacterial killing (C) againstB.
pseudomallei in purified human PMNs (N = 5). Rabbit anti-FliCBp, pre-bleed anti-sera at dilution 1:50 or anti-predicted peptide antibodies at 40 g/ml were
used for opsonization. * P < 0.05, ** P < 0.01, *** P < 0.001, ns, not significant compared between with or without antibody groups using one-tailed paired t
test.
doi:10.1371/journal.pntd.0003917.g005
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resolution of 1.3 Å by molecular replacement, using the structure of domain D1 (residues 62–
168 and 281–326) of Sphingomonas sp. A1 flagellin (PDB entry 2ZBI) as an initial search
model, and refined to satisfactory Rgen and Rfree values of 13.6% and 16.4%, respectively (statis-
tics for the data collection and model refinement are shown in S1 Table). Electron density was
visible for residues 69–326; the first 44 N-terminal residues and the 52 C-terminal residues
were absent, however experimental epitope mapping revealed two immunocaptured peptides
containing N-terminal residue 37 and residue 361, therefore the residues that are not visible in
the electron density are likely to be present in disordered regions of the protein.
Flagellins vary in dimension (28–65 kDa) and contain at least two essential highly conserved
domains, D0 and D1 that mediate assembly of the flagellar filament, and may contain a second
(D2) or third (D3) variable domain. Typically, removal of the D0 domain is necessary for suc-
cessful crystallization. This was not the case for FliCBp where, however, the first 44 N-terminal
residues (corresponding to the D0 domain) are not visible in the electron density map because
of structural disorder. Overall, FliCBp adopts the canonical flagellin fold and presents two
domains, a conserved D1 domain (residues 69–167, 287–326), and a variable D2 domain (168
and 286) (Fig 6). D1 forms a helical rod (α1, α2 and α5) involving residues contributed by both
the N-terminus (residues 69–170) and C-terminus (residues 285–326), a β-hairpin domain
(β1-β2) and a 310 α-helix (η1). Domain D2 (residues 172–287) contains a three-stranded anti-
parallel β-sheet, two α−helices (α3 and α4) and two 310 α-helices (η2 and η3). Domain D2 is
connected to D1 via two anti-parallel regions that house two short 310 α-helices (η1 and η3)
that interact with each other, thus stabilizing the relative positions of the two domains (Fig 6).
The closest structural homolog to FliCBp available in the Protein Data Bank is flagellin from
Pseudomonas aeruginosa (FliCPa; PDB entry 4NX9) [50], with whom it shares 36.5% sequence
identity and 96.2% secondary structure similarity and a rms deviation of 1.34 Å over 168
aligned Cα pairs (S4 Fig). The structural similarity is limited to the D1 domains, while domain
D2 is different in FliCBp and FliCPa. The main difference arises due to the 7 β-strands present
in the D2 domain of FliCPa in comparison with three present in FliCBp (S4 Fig). Furthermore,
due to the diverse tertiary positioning of the D2 domains, when the D1 domains are aligned,
the D2 domains do not superimpose (S4 Fig).
Both D1 and D2 domains have been shown to be important for innate immune recognition
[51,52]. With regards to the location of the predicted epitope peptides on the 3D structure,
F51-69 could not be mapped onto the structure as electron density was absent for this region,
indicating that it is likely to be non-structured. F96-111 is housed in domain D1 and is com-
posed of two short α-helical segments at the C- and N- termini of α-helices 1 and 2, connected
by a short loop.
The third predicted peptide F270-288, is located in domain D2 and is formed by α-helix 4,
the 310 α-helices η3, and their connecting loop region (Fig 6).
Structure-based prediction of FliCBp B- and T-cell epitopes via MLCE
and EDPmethods
In the context of a Structural Vaccinology project, structure-based computational epitope pre-
dictions have proved successful for the identification and design of B. pseudomallei epitopes
with improved immunological properties in comparison with their cognate recombinant pro-
teins, commencing from the crystal structures of the target antigens [41,53].
In order to expand the investigation on FliCBp beyond the reach of the bioinformatics
sequence-based predictions, and possibly complementing it, we employed two structure-based
computational methods for epitope identification, and compared the results with the previous
consensus. The newly solved 3D structure of the antigen, allows taking a different perspective
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on epitope discovery. Here, two complementary computational methods for epitope prediction
were combined and applied to representative structures obtained from molecular dynamics
(MD) simulations run on the FliCBp crystal structure (see Materials and Methods) [54]. MLCE
selects antigenic B- and T-cell epitopes while the EDP identifies general protein-protein inter-
action interfaces. Predictions produced individually by MLCE and EDP are aligned with the
sequence-based consensus and presented in S5 Fig.
Experimental B-cell epitope mapping
Epitope mapping experiments were carried out using recombinant FliCBp and cognate poly-
clonal sera. To this aim, we adopted and extended an immunocapturing approach successfully
used previously with monoclonal antibodies [55]. The approach involves proteolytic digestion
(using diverse proteases) of the target antigen prior to immunocapturing, and subsequent anal-
ysis of antibody-bound peptides (containing epitopes or fragments thereof) by mass spectrom-
etry. Using trypsin for the partial digestion of FliCBp, 5 different peptides were captured by the
polyclonal IgGs and subjected to MS/MS analysis: a 1529.807 Da peptide corresponding to the
N-terminal segment 37-INSAADDAAGLAIATR-52 (1529.6 Da); a peptide of 2231.122 Da
corresponding to 300-QAMVSIDNALATVNNLQATLGAAQNR-325 (2685 Da); two
Fig 6. Domain organization and 3D crystal structure of FliCBp. Schematic secondary structure ribbon
representation of the crystal structure of FliCBp. The N- and C-termini are labeled as are the diverse
secondary structural features with α-helices in cyan and β-strands in magenta. Peptides 96–111, 213–233
and 270–288 are highlighted in red, green and black, respectively. This figure was produced using
MacPymol.
doi:10.1371/journal.pntd.0003917.g006
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2771.356 Da and 3310.671 peptides Da represented the same region of the protein with seg-
ment 98-ASNGPLSASDASALQQEVAQQISEVNR-124 (2770.9 Da) and 93-QLAV-
QASNGPLSASDASALQQEVAQQISEVNR-124 (3310.5 Da), and a 3782.885 Da peptide
corresponding to 326-FTAIATTQQAGSNNLAQAQSQIQSADFAQETANLSR-361 (3783 Da)
(S5 Fig).
Selection of an additional T-cell epitope and in vitro characterization
Overall, the addition of experimental mapping, as well as EDP and MLCE analysis confirm the
accuracy of the previous results, being among the areas of the alignment displaying the best
consensus (S5 Fig). The other putative active epitopes, consisting of the overlap of two or more
methods, include fragments V148-T155; D188-T203; G236-F250 and L309-F326. According to
the new consensus, these sequences represent good candidates for further tests of immune rec-
ognition, and are currently being investigated.
Among the activities presented in this communication, we selected an additional T cell epi-
tope to be tested, based on the consensus between IEDB (sequence based) (Table 1) and MLCE
(structure-based) (S5 Fig), both having specificity for T-cell epitopes. The linear stretch
K213-V231 is not selected by any other B cell specific prediction method, and may be an inter-
esting candidate to be assessed for T cell activation. In the 3D FliCBp structure, this peptide
mainly is formed by α-helix 3 and β-strand 7 that pertain to Domain 2 (Fig 6). We synthesized
the new epitope F213-231 and repeated the experiment of PBMC stimulation for cytokine pro-
duction (Fig 4). This peptide epitope was shown to stimulate IFN-γ production in 8/20 samples
(40%) and IL-10 production in all 20 samples tested (100%). These results correlate with our
previous results that show that this peptide segment can elicit IFN-γ [19]. In parallel, we
assessed immune sera recognition of epitope F213-231 and observed that it is not seroreactive,
suggesting that it is a potential T-cell epitope but not a B cell epitope (Fig 3C).
Discussion
In the melioidosis vaccine development field, several protein antigens have been tested for
their ability to trigger a protective immune response in animal models of disease, however, pro-
tection has proven to be limited in all cases [7]. In addition to the adaptive immune response,
innate immunity also plays an important role in resistance to B. pseudomallei infection [3,56].
Neutrophils are one of the key players in cellular immunity that stimulate bacterial killing,
both directly or indirectly via cytokine production [57,58]. Therefore, it is likely that a future
melioidosis vaccine should comprise antigens/epitopes that trigger both arms of the immune
system.
Table 1. Analysis of predicted B cell FliCBp epitopes as potential human T cell epitopes using the HLA binding predictor from Immunoepitope
Database (IEDB), focusing on common HLA-DRB1 types in the Thai population.
Predicted sequences HLA binding predicted score (DRB1)
03:01 04:05 07:01 09:01 12:02 14:01 15:01 15:02 16:01
F51-69 51TRMQTQINGLNQGVSNAND69 53.34 23.03 70.21 50.47 54.56 65.29 30.06 20.71 69.72
F96-111 96VQASNGPLSASDASAL111 15.32 23.79 38.89 21.31 83.10 88.80 52.17 19.15 90.09
F166-180 166AAKIGGGMVQTGQTL180 70.94 51.67 66.32 61.16 80.81 87.30 36.27 28.49 80.25
F189-207 189DSSGAAWSSGSTGQETTQIN207 70.94 49.39 66.27 52.87 97.57 98.29 75.97 30.22 94.40
F236-250 236GSSTAGTGTAASPSF250 70.15 47.07 53.65 61.16 95.21 98.44 68.85 34.99 92.62
F270-288 270NATAMVAQINAVNKPQTVS288 21.55 12.28 52.37 30.81 26.30 22.33 22.39 18.87 41.22
F213-231 213KGGFTFTDQNNQALSST231 30.37 29.68 44.85 45.27 78.14 53.65 48.85 26.26 63.35
doi:10.1371/journal.pntd.0003917.t001
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Antigen design guided by computational biology is at the forefront of vaccine development,
focusing on the design of only immunogenic portions of the antigen that may be domains or
even linear peptides. In fact, epitopes may display elevated antigenic activities in comparison
with their parental antigen, as previously observed for two acute phase antigens from B. pseu-
domallei [41,53].
In this context, we focused on flagellin from B. pseudomallei as a target for epitope discovery
and design, using both sequence-based and 3D structure based approaches. Flagellins from
diverse bacteria have been studied as subunit vaccine candidates; among these, S. typhimurium
FliC induces responses from Th2 in primary immunization tests, followed by Th1-dependent
responses that occur later during subsequent infection, which leads to bacterial clearance [59].
Furthermore, protective antibody production against B. pseudomallei infection has also been
reported for mice immunized through a modified plasmid encoding the fliC gene, combined
with CpG oliogodeoxynucleotide [11]. Several immunogenic epitopes have been identified
from FliC homologs, e.g. FliC from Borrelia burgdoferi [60] and FliC from Salmonella typhi-
murium, from which four epitopes were identified as CD4+ specific T cells epitopes [61,62].
Using sequence-based computational predictions, we identified and synthesized three pep-
tides (F51-69, F96-111 and F270-288) with predicted T-cell and B-cell stimulatory activities.
Two peptides (F51-69 and F270-288) were in fact found to be B-cell epitopes and were reactive
against human antibodies (IgG) isolated from melioidosis-infected subjects and healthy sero-
positive subjects. The third peptide (F96-111) was not reactive with sera and, based on 3D-
structural considerations, and in light of the crystal structure here presented, it is unlikely to be
accessible to antibodies when FliC is assembled in the flagella. In fact, structural comparisons
of FliCBp and S. typhimurium flagellin (FliCSt), for which several structural and flagellin assem-
bly studies have been carried out, indicate that F96-111 is housed in a key site that in FliCSt
mediates axial interactions and protofilament assembly, being also responsible for TLR5 recog-
nition of the monomeric protein [63,64]. As only monomeric FliC activates TLR5, it has been
suggested that cellular recognition of FliC requires flagella degradation, for example via phago-
cytosis or other depolymerization mechanisms [63]. Such an interface location for F96-111 in
the assembled protofilament structure was confirmed by the inability of anti-F96-111 antibod-
ies to recognize crude B. pseudomallei extract, and accounts for the fact that the epitope was
not recognized by human antibodies. Thus, while it remains a possible T-cell epitope, F96-111
is unlikely to be a B-cell epitope in FliCBp oligomeric native state.
Based on sequence alignment with FliCSt for which residues involved in intermolecular fla-
gellin contacts are known [63,64], F51-69 should also be part of the assembly interface, and
should be buried in the flagella, thus inaccessible to antibodies. However, residues 51–69 are
absent in the FliCBp structure, suggesting that they are structurally disordered, in contrast to
equivalent residues from FliCSt that instead pertain to the N- terminal α-helix, suggesting that
the assembly interfaces may differ between the species. In fact, the F51-69 peptide is recognized
by human antibodies, demonstrating that this region is accessible in the flagella and not buried
as in FliCSt.
With regards to the cell-mediated response, our results show that all predicted T/B cell
FliCBp epitopes (in particular F51-69) induce cytokine production (IFN-γ and IL-10) from
human PBMCs, and that their cognate antibodies also enhance human PMN phagocytosis and
bacterial killing by increasing oxidative burst activity.
We also report the 1.3Å resolution FliCBp crystal structure as the basis for in silico epitope
predictions using two diverse computational methods. Our approach, besides allowing us to
cross-validate sequence-based and 3D-structure-based epitope prediction methods (resulting
in the identification of consensus epitope regions), identified a fourth epitope (F213-231) that,
when synthesized as a peptide, was found to be a T-cell epitope but not a B-cell epitope.
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Significantly, the in silico (structure and sequence-based) predictions were complemented by
in vitro epitope mapping that identified residues predicted by both sequence-based and struc-
ture-based methods.
As previously mentioned, it is likely that several protective antigens will be required to for-
mulate an effective protective vaccine [7,65]. Previous experimentation on mice immunization
showed that the addition of adjuvants is often necessary in combination with subunit vaccine
candidates to elicit protection [65]. TLR agonists are widely used as adjuvants, including flagel-
lin, which is a TLR5 agonist and a potent activator of both the innate and adaptive immune
responses [18,50]. This implies that the potential of the T-cell/B-cell FliCBp peptides identified
in this study could represent adjuvants to be administered with other antigen candidates to
develop a protective melioidosis vaccine. In fact, a truncated form of FliCSt was shown to
induce a significantly stronger cellular immune response when administered in a chimeric sub-
unit vaccine together with Eimeria tenella immune mapped protein-1 (EtIMP1), in comparison
to Freund’s Complete Adjuvant [66]. An additional successful application of FliC as a carrier
protein was reported for the glycoconjugate subunit vaccine that improved protection against
fetal infection disease [67].
In conclusion, our results shows that both sequence-based and 3D-structure-based epitope
discovery methods, and the derived consensus sequence segments, proved successful in the
identification of both T-cell and B-cell epitopes from FliCBp. Validatory in vitro epitope map-
ping and immunological tests fully confirmed the predictive analyses. Taken together, our data
suggest that the predicted peptide epitopes with confirmed T-cell/B-cell activities should pro-
ceed to further in vivo immunological tests as potential vaccine components, possibly in con-
junction with other known B. pseudomallei antigens. To this aim, further analyses of additional
peptides suggested by the 3D-structure-based predictions will be undertaken to enrich the rep-
ertoire of potential protective epitopes.
Supporting Information
S1 Fig. Phagocytosis and oxidative burst assay gating strategy and analysis. Purified PMN
cells were gated on the basis of their FSC/SSC. All gates were identical in all samples within
each experiment. The degree of phagocytosis and oxidative burst is shown by fluorescent inten-
sities of FL1-FITC and FL2-EB, respectively. FL1-fluorescent channel 1; FL2-fluorescent chan-
nel 2; FITC-fluorescein isothiocyanate; EB-ethidium bromide.
(TIF)
S2 Fig. Rabbit antibodies raised against F51-69 (A), F96-111 (B) F270-288 peptides (C),
recombinant FliCBp (D), and prebleed serum (E) recognize crude B. pseudomallei, recombi-
nant FliCBp and predicted peptides (A-D). Results are represented by pre-bleed subtracted O.
D. (O.D.antisera-O.D.pre-bleed) with error bar. Experiments were performed in duplicate.
(TIF)
S3 Fig. B. pseudomallei protein and peptides neutralize human antibody activity. Crude B.
pseudomallei antigens, FliCBp peptide F51-69, F96-111, F270-288, F213-231 were coated onto a
96-well polystyrene plate and probed with peptide/protein pre-incubated plasma samples and
quantified by Indirect ELISA. Results are represented as Absorbance index (O.D. test-O.D.
uncoated / O.D. uncoated). Experiments were performed in duplicate.
(TIF)
S4 Fig. Structural comparison of FliCBp and FliCPa. Secondary structure representation of
the superimposed 3D structures of FliCBp (magenta ribbons) and FliCPa (PDB entry 4NX9;
cyan ribbons). Superimposition of the C-alpha atoms of the two structures was carried out
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using the C-alpha match server (http://bioinfo3d.cs.tau.ac.il/c_alpha_match/) [68]. This figure
was produced using Pymol.
(TIFF)
S5 Fig. Comparison of structure-based in silico epitope predictions with in vitro immuno-
captured peptides and synthesized T-cell/B-cell peptides. FliCBp full-length sequence illus-
trating epitope residues predicted by MLCE (blue), EDP (green) from the FliCBp crystal
structure, the consensus of three (BepiPred, BCPred and AAC) B-cell sequence-based predic-
tion servers (purple), experimentally mapped peptides (red) and the four synthesized peptides
(orange) that represent the consensus of both B-cell and T-cell online sequence-based predic-
tors, and the MLCE-identified peptide. Grey shaded boxes indicate residues shared between
more than two or more independent identification methods. The N- and C-terminal residues
visible in the electron density of the structure are underlined.
(TIF)
S1 Table. Data collection and refinement statistics for FliCBp. A single data collection
allowed solving the structure. Rmerge = SI-(I) S I x 100, where I is the intensity of a reflection
and (I) is the average intensity; Rfree was calculated from 5% of randomly selected data for
cross-validation; R-factor = SFo-Fc/SFo x 100.
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